单线态氧
光动力疗法
光敏剂
前药
化学
活性氧
癌症研究
超氧化物
NAD+激酶
癌细胞
生物安全
赫拉
生物物理学
DNA损伤
组合化学
线粒体
细胞
氧气
细胞凋亡
癌症治疗
癌症治疗
纳米颗粒
DNA
联合疗法
纳米技术
癌症
细胞生长
氧化还原
肿瘤细胞
氧合物
光化学
药理学
作者
Haoran Hou,Hanhan Lu,Yingnan Wu,Tai Sun,Gaobo Hong,Yanliang Zhao,Jianjun Du,Fengling Song,Xiaojun Peng
出处
期刊:Small
[Wiley]
日期:2026-08-18
卷期号:22 (59)
摘要
ABSTRACT The oxygen heterogeneity within tumors restricts the therapeutic efficacy of hypoxia‐activated prodrugs (HAPs) and traditional photosensitizers (PSs) when administered alone. To overcome this limitation, we present an oxygen‐unrestricted synergistic therapeutic strategy to concurrently potentiate treatment efficacy in both hypoxic and normoxic tumor compartments. By introducing TEMPO, we developed an efficient PS capable of simultaneous Type I and Type II photocatalytic reactions. This PS, named DT , was co‐encapsulated with the HAP TH‐302 into a tumor‐targeting nanoparticle system, DT@TH302 , which exhibits mitochondrial localization. Upon photoactivation, DT@TH302 generates substantial amounts of singlet oxygen and superoxide anion, while disrupting the cellular NAD + /NADH redox equilibrium, leading to catastrophic mitochondrial dysfunction. The oxygen consumption during photodynamic therapy (PDT) further aggravates local hypoxia, thereby activating TH‐302 to induce DNA cross‐linking and promote tumor cell apoptosis. Meanwhile, DT‐mediated PDT remains effective through a hypoxia‐tolerant Type I mechanism. Moreover, the treatment triggers immunogenic cell death, demonstrating considerable potential for immunotherapy. In vivo, DT@TH302 exhibits excellent biosafety and tumor‐targeting capability, resulting in significant tumor growth suppression. This work provides an oxygen‐unrestricted synergistic strategy to compensate for the limitations of standalone Type II PSs or HAPs monotherapy, offering valuable insights for clinical cancer treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI